Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO

Chinese oncology drug developer Tot Biopharm raises $75.2m in HK IPO

Photo by Louis Reed on Unsplash

08 November, 2019

biopharmaceutical Centerlab Oncology Tot Biopharm Vivo Capital

Printed by Unregistered user on Sat, 06 Dec 2025 05:38:14 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China Renaissance-backed Bloomage Biotech raises $338m in Shanghai IPO

Hong Kong biotech firms seek listings on China’s Star Board

Read more from Greater China

Alibaba to retire Ele.me brand amid instant-retail push

HongShan aims for $2.9b sale of Golden Goose to Permira by Christmas: report